ALK2 and JAK2 Inhibition for Improved Treatment of Anemia in Myelofibrosis Patients: Preclinical Profile of an ALK2 Inhibitor Zilurgisertib in Combination with Ruxolitinib

被引：1
|
作者：
Stubbs, Matthew C. [1 ]
Pusey, Michelle [1 ]
Wen, Xiaoming [1 ]
Drake, Katherine [1 ]
Zolotarjova, Nina [1 ]
Smith, Amanda [1 ]
Covington, Maryanne [1 ]
Zhang, Guofeng [1 ]
Macarron, Ricardo [2 ]
Kim, Sunkyu [1 ]
机构：
[1] Incyte Res Inst, Wilmington, DE USA
[2] Incyte, Wilmington, PA USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-181055
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] BLU-782; a highly selective ALK2 inhibitor, designed specifically to target the cause of fibrodysplasia ossificans progressiva
    Davis, Alison
    Hodous, Brian
    Labranche, Timothy
    Sheets, Michael
    Brooijmans, Natasja
    Kim, Joseph
    Williams, Brett
    Kim, Sean
    Xu, Lan
    Vassiliadis, John
    Zhu, Julia
    Wang, Ruduan
    Stewart, Rachel
    Fleming, Paul
    Graul, Chris
    Greenblatt, Elliot
    Bouchard, Keith
    Kadambi, Vivek
    Guzi, Timothy
    Hunter, Jeffrey
    Lengauer, Christoph
    Dorsch, Marion
    Garner, Andrew
    JOURNAL OF BONE AND MINERAL RESEARCH, 2018, 33 : 26 - 26
  • [42] ALK2 inhibitors display beneficial effects in preclinical models of ACVR1 mutant diffuse intrinsic pontine glioma
    Carvalho, Diana
    Taylor, Kathryn R.
    Olaciregui, Nagore Gene
    Molinari, Valeria
    Clarke, Matthew
    Mackay, Alan
    Ruddle, Ruth
    Henley, Alan
    Valenti, Melanie
    Hayes, Angela
    Brandon, Alexis De Haven
    Eccles, Suzanne A.
    Raynaud, Florence
    Boudhar, Aicha
    Monje, Michelle
    Popov, Sergey
    Moore, Andrew S.
    Mora, Jaume
    Cruz, Ofelia
    Vinci, Mara
    Brennan, Paul E.
    Bullock, Alex N.
    Carcaboso, Angel Montero
    Jones, Chris
    COMMUNICATIONS BIOLOGY, 2019, 2 (1)
  • [43] ALK2 inhibitors display beneficial effects in preclinical models of ACVR1 mutant diffuse intrinsic pontine glioma
    Diana Carvalho
    Kathryn R. Taylor
    Nagore Gene Olaciregui
    Valeria Molinari
    Matthew Clarke
    Alan Mackay
    Ruth Ruddle
    Alan Henley
    Melanie Valenti
    Angela Hayes
    Alexis De Haven Brandon
    Suzanne A. Eccles
    Florence Raynaud
    Aicha Boudhar
    Michelle Monje
    Sergey Popov
    Andrew S. Moore
    Jaume Mora
    Ofelia Cruz
    Mara Vinci
    Paul E. Brennan
    Alex N. Bullock
    Angel Montero Carcaboso
    Chris Jones
    Communications Biology, 2
  • [44] Molecular mechanisms of the activation of BMP signaling by ligands through ALK2/ACVR1 receptor and the inhibition of signaling by an anti-ALK2/ACVR1 antibody
    Katagiri, Takenobu
    Tsukamoto, Sho
    Kuratani, Mai
    Tsuji, Shinnosuke
    Takaishi, Kiyosumi
    Kunikata, Tomonori
    Nakamura, Kensuke
    Kawaguchi, Yoshiro
    JOURNAL OF BONE AND MINERAL RESEARCH, 2022, 37 : 117 - 117
  • [45] The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation
    Ikeda, Kazuhiko
    Ueda, Koki
    Sano, Takahiro
    Ogawa, Kazuei
    Ikezoe, Takayuki
    Hashimoto, Yuko
    Morishita, Soji
    Komatsu, Norio
    Ohto, Hitoshi
    Takeishi, Yasuchika
    INTERNAL MEDICINE, 2017, 56 (13) : 1705 - 1710
  • [46] A constitutively activated BMP receptor, ALK2, induces heterotopic bone formation in patients with Fibrodysplasia Ossificans Progressiva (FOP)
    Fukuda, T.
    Kohda, M.
    Kanomata, K.
    Nojima, J.
    Kamizono, J.
    Oda, H.
    Nakayama, K.
    Ohtake, A.
    Miyazono, K.
    Jimi, E.
    Owan, I.
    Okazaki, Y.
    Katagiri, T.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2007, 22 : S10 - S10
  • [47] Phase II trial of Lestaurtinib, a JAK2 inhibitor, in patients with myelofibrosis
    Mascarenhas, John
    Baer, Maria R.
    Kessler, Craig
    Hexner, Elizabeth
    Tremblay, Douglas
    Price, Leah
    Sandy, Lonette
    Weinberg, Rona
    Pahl, Heike
    Silverman, Lewis R.
    Goldberg, Judith D.
    Kosiorek, Heidi
    Dueck, Amylou C.
    Hoffman, Ronald
    LEUKEMIA & LYMPHOMA, 2019, 60 (05) : 1343 - 1345
  • [48] Novel bicyclic pyrazoles as potent ALK2 (R206H) inhibitors for the treatment of fibrodysplasia ossificans progressiva
    Yamamoto, Hirofumi
    Sakai, Naoki
    Ohte, Satoshi
    Sato, Tomohiro
    Sekimata, Katsuhiko
    Matsumoto, Takehisa
    Nakamura, Kana
    Watanabe, Hisami
    Mishima-Tsumagari, Chiemi
    Tanaka, Akiko
    Hashizume, Yoshinobu
    Honma, Teruki
    Katagiri, Takenobu
    Miyazono, Kohei
    Tomoda, Hiroshi
    Shirouzu, Mikako
    Koyama, Hiroo
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2021, 38
  • [49] Anti-Myeloma Activity by the Combination of the JAK2 Inhibitor Ruxolitinib with Lenalidomide and Corticosteroids
    Chen, Haiming
    Sanchez, Eric
    Li, Mingjie
    Wang, Cathy
    Gillespie, Abby
    Shvartsur, Anna
    Vardanyan, Suzie
    Harutyunyan, Nika M.
    Garzio, Gigi
    Tang, George
    Bonavida, Benjamin
    Berenson, James R.
    BLOOD, 2014, 124 (21)
  • [50] Administration of KER-047, a Novel ALK2 Inhibitor, Elicited Robust and Sustained Increases in Serum Iron in Healthy Participants
    Ordonez, Claudia
    Ben, Snyder
    Barger, Rachel
    Serino, Timna
    Tseng, Claire C.
    Rovaldi, Christopher
    Lachey, Jenn
    Seehra, Jasbir
    BLOOD, 2020, 136
12345